Published in J Subst Abuse Treat on June 24, 2016
Contingency Management: New Directions and Remaining Challenges for An Evidence-Based Intervention. J Subst Abuse Treat (2016) 0.75
A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction (2006) 8.57
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet (2011) 6.21
A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep (2006) 5.63
Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis (2001) 5.43
Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet (2001) 5.28
Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health (2001) 4.57
Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr (2006) 4.45
A review of delay-discounting research with humans: relations to drug use and gambling. Behav Pharmacol (2006) 4.41
Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trial. Lancet (2014) 3.58
The Demand for, and Impact of, Learning HIV Status. Am Econ Rev (2008) 3.25
Prize reinforcement contingency management for treating cocaine users: how low can we go, and with whom? Addiction (2004) 3.06
An experimental comparison of three different schedules of reinforcement of drug abstinence using cigarette smoking as an exemplar. J Appl Behav Anal (1996) 2.98
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med (2014) 2.54
Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City. AIDS (2007) 2.52
Sex related HIV risk behaviors: differential risks among injection drug users, crack smokers, and injection drug users who smoke crack. Drug Alcohol Depend (2000) 2.51
Cue-dose training with monetary reinforcement: pilot study of an antiretroviral adherence intervention. J Gen Intern Med (2000) 2.45
The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review. BMC Public Health (2009) 2.39
A within-subject comparison of three different schedules of reinforcement of drug abstinence using cigarette smoking as an exemplar. Drug Alcohol Depend (2000) 2.35
Voucher-based reinforcement of cocaine abstinence in treatment-resistant methadone patients: effects of reinforcement magnitude. Psychopharmacology (Berl) (1999) 2.30
Do research payments precipitate drug use or coerce participation? Drug Alcohol Depend (2005) 2.26
Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep (2011) 2.18
A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users. Am J Med (2001) 2.15
Promoting healthy behaviours and improving health outcomes in low and middle income countries: a review of the impact of conditional cash transfer programmes. Prev Med (2011) 2.13
Contingency management for treatment of substance abuse. Annu Rev Clin Psychol (2006) 2.13
A randomized controlled trial of monetary incentives vs. outreach to enhance adherence to the hepatitis B vaccine series among injection drug users. Drug Alcohol Depend (2003) 1.99
Tuberculosis prophylaxis in the homeless. A trial to improve adherence to referral. Arch Intern Med (1996) 1.92
Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial. Drug Alcohol Depend (2006) 1.92
The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. J Acquir Immune Defic Syndr (2006) 1.71
Epidemiology and prevention of hepatitis B. Semin Liver Dis (2003) 1.71
Higher magnitude cash payments improve research follow-up rates without increasing drug use or perceived coercion. Drug Alcohol Depend (2008) 1.67
Tuberculosis screening and compliance with return for skin test reading among active drug users. Am J Public Health (1998) 1.56
Alcohol use in HIV patients: what we don't know may hurt us. Int J STD AIDS (1999) 1.48
Material incentives and enablers in the management of tuberculosis. Cochrane Database Syst Rev (2012) 1.47
Adherence to isoniazid prophylaxis in the homeless: a randomized controlled trial. Arch Intern Med (2000) 1.44
Management of hepatitis C. NIH Consens Statement (1998) 1.44
HIV infection and risk, prevention, and testing behaviors among injecting drug users -- National HIV Behavioral Surveillance System, 20 U.S. cities, 2009. MMWR Surveill Summ (2014) 1.31
Can the poor adhere? Incentives for adherence to TB prevention in homeless adults. Int J Tuberc Lung Dis (2004) 1.31
Incentives vs outreach workers for latent tuberculosis treatment in drug users. Am J Prev Med (2001) 1.30
Treatment of heroin-dependent poly-drug abusers with contingency management and buprenorphine maintenance. Exp Clin Psychopharmacol (2000) 1.29
A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users. Drug Alcohol Depend (2002) 1.28
Vaccination strategies for targeted and difficult-to-access groups. Am J Public Health (2000) 1.22
Discounting of money, health, and freedom in substance abusers and controls. Drug Alcohol Depend (2003) 1.20
Monetary versus nonmonetary incentives for TB skin test reading among drug users. Am J Prev Med (1999) 1.18
The effects of increasing incentives on adherence to tuberculosis directly observed therapy. Int J Tuberc Lung Dis (2000) 1.17
Voucher incentives improve linkage to and retention in care among HIV-infected drug users in Chennai, India. Clin Infect Dis (2014) 1.17
Crack cocaine use and other risk factors for tuberculin positivity in drug users. Clin Infect Dis (2002) 1.14
Contingency management in substance abuse treatment: a structured review of the evidence for its transportability. Drug Alcohol Depend (2011) 1.14
Effects of an incentive and education program on return rates for PPD test reading in patients with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.11
Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. J Viral Hepat (2008) 1.10
Risk factors for and knowledge of Mycobacterium tuberculosis infection among drug users in substance abuse treatment. Addiction (1998) 1.10
Randomized controlled trial of interventions to improve follow-up for latent tuberculosis infection after release from jail. Arch Intern Med (2002) 1.09
Mycobacterium tuberculosis cluster with developing drug resistance, New York, New York, USA, 2003-2009. Emerg Infect Dis (2011) 1.07
Modified directly observed therapy (MDOT) for injection drug users with HIV disease. Am J Addict (2002) 1.06
Nemesis revisited: tuberculosis infection in a New York City men's shelter. Am J Public Health (1993) 1.05
Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates). Dig Liver Dis (2011) 1.03
A spoonful of sugar...: improving adherence to tuberculosis treatment using financial incentives. Int J Tuberc Lung Dis (2001) 1.02
Drug users' adherence to a 6-month vaccination protocol: effects of motivational incentives. Drug Alcohol Depend (2009) 1.02
Tuberculosis and HIV in people who inject drugs: evidence for action for tuberculosis, HIV, prison and harm reduction services. Curr Opin HIV AIDS (2012) 1.00
A clinical trial of a financial incentive to go to the tuberculosis clinic for isoniazid after release from jail. Int J Tuberc Lung Dis (1998) 0.99
Use of incentives to increase compliance for TB screening in a population of intravenous drug users. Vancouver Injection Drug Use Study Group. Int J Tuberc Lung Dis (1999) 0.97
Accelerated hepatitis B vaccination schedule among drug users: a randomized controlled trial. J Infect Dis (2010) 0.97
Contingency management interventions for HIV-related behaviors. Curr HIV/AIDS Rep (2006) 0.94
Chronic hepatitis C in alcoholic patients: prevalence, genotypes, and correlation to liver disease. Scand J Gastroenterol (1995) 0.92
The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs. AIDS (2015) 0.89
A randomised controlled trial of financial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia. Prev Med (2013) 0.88
Contingency management in cocaine abusers: a dose-effect comparison of goods-based versus cash-based incentives. Exp Clin Psychopharmacol (2007) 0.88
A study of financial incentives to reduce plasma HIV RNA among patients in care. AIDS Behav (2013) 0.86
Hepatitis B in the United States: ongoing missed opportunities for hepatitis B vaccination, evidence from the Behavioral Risk Factor Surveillance Survey, 2007. Infection (2012) 0.83
Impact of monetary incentives on adherence to referral for screening chest x-rays after syringe exchange-based tuberculin skin testing. J Urban Health (2003) 0.81
The emergence of meticillin-resistant Staphylococcus aureus among injecting drug users. J Infect (2009) 0.79
Stavudine, lamivudine and indinavir in drug abusing and non-drug abusing HIV-infected patients: adherence, side effects and efficacy. J Infect (1999) 0.76